Description

Description: Study the spike protein from SARS-CoV-2 Variant P1, a CDC variant of concern, with this packaging mix for lentivirus pseudotyped with the P1 spike proteinBased on SBI’s popular and highly cited pPACKH1 Packaging SystemUses codon-optimized SARS-CoV-2 “S” protein from variant P1 in place of VSV-G envelope proteinSpike protein mutations are L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176FIdeal for vaccine and antiviral efficacy studies under BSL2 conditionsPackage any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reportersOverviewSafely study the spike protein from emerging SARS-CoV-2 variantsClassified as a variant of concern by the Centers for Disease Control (CDC) in the United States, the SARS-CoV-2 P1 Variant has been a major driver of disease in Brazil and shows increased transmissibility [1] and increased resistance to neutralization [2]. With the pPACK-SPIKE™ P1 Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from the emerging lineage P1, which contains the following mutations:L18FT20NP26SD138YR190SK417TE484KN501YD614GH655YT1027IV1176FDesigned to efficiently package most third-generation lentivectors, the pPACK-SPIKE P1 Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects. Based on SBI’s highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE P1 Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.Based on SBI’s popular and highly cited pPACKH1 Packaging System. Uses codon-optimized SARS-CoV-2 “S” protein from variant P1 in place of VSV-G envelope proteinSpike protein mutations are L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F. Ideal for vaccine and antiviral efficacy studies under BSL2 conditionsPackage any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reportersCompare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants. Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative controlp PACK-SPIKE P1 Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.